Potential Biomarker Of Disease Progression Research Articles

The possible role of oxidative stress marker glutathione in the assessment of cognitive impairment in multiple sclerosis.

Oxidative stress markers have a distinct role in the process of demyelination in multiple sclerosis. This study investigated the potential correlation of markers of oxidative stress (glutathione [GSH], catalase) with the number of demyelinating lesions and the degree of disability, cognitive deficit, and depression in patients with relapsing-remitting multiple sclerosis (RRMS). Sixty subjects meeting the criteria for RRMS (19 men and 41 women), and 66 healthy controls (24 men, 42 women) were included. In this study, GSH significantly negatively correlated with the degree of cognitive impairment. This is the first study of subjects with RRMS that performed the mentioned research of serum GSH levels on the degree of cognitive damage examined by the Montreal Scale of Cognitive Assessment (MoCA) test. The development of cognitive changes, verified by the MoCA test, was statistically significantly influenced by the positive number of magnetic resonance lesions, degree of depression, expanded disability status scale (EDSS), age, and GSH values. Based on these results, it can be concluded that it is necessary to monitor cognitive status early in RRMS patients, especially in those with a larger number of demyelinating lesions and a higher EDSS level and in older subjects. Also, the serum level of GSH is a potential biomarker of disease progression, which could be used more widely in RRMS.

Investigation of Genes and Their Interactions in Liver Diseases Using Bioinformatics Algorithms

In this study, we considered progression of liver diseases. Particularly we considered Hepatocellular Carcinoma Cancer, HCC, whose patients have low survival rates. For this purpose, we researched molecular structures and protein interactions involved in the initiation and progression of HCC. We exploited microarray data samples and their gene expression profiles from literature. During analysis, we implemented statistical data analysis techniques and looked for Differentially Expressed Genes during the initiation and progression of HCC. As a result of this analysis we found 12 hub genes, where 3 of them (ANLN, TOP2A, ASPM and SPINK1) were upregulated and the others (CXCL14, LINC01093, OIT3, CLEC4G, THRSP, APOF, CLTRN and FCN3) were downregulated. By performing Gene Ontology Analysis, we classified genes with increased or decreased expressions in terms of cellular component, biological process, and molecular function. Subsequently, we executed protein-protein interaction network analysis and found important interactions between the hub genes. Results of data analysis concluded that these 12 genes and their interactions play a key role in the initiation and progression of significant liver diseases and can be used as a potential biomarker for disease progression. Furthermore, gene feature analysis showed that it is becoming more difficult to compensate functional deficiencies of the proteins encoded by these genes during biological processes. In particular, Gene Ontology Analysis denoted that TOP2A gene associates with many of the biological pathways and a change in the expression of this gene can cause decent problems in many cellular functions.

Neuregulin 1 as a potential biomarker for disease progression in moyamoya disease: A case-control study in Chinese population

ObjectiveMoyamoya disease (MMD) is a rare and progressive stenosis of cerebral arteries characterized by abnormally proliferative vasculopathy. Current studies have demonstrated that Neuregulin 1 (NRG1) plays a key role in angiogenesis-related disorders. Thus, the aim of our study is to investigate the serum NRG1 levels and their clinical correlations in MMD patients. MethodsIn this study, thirty adult patients with MMD and age-gender matched healthy controls were enrolled from our hospital between July 2020 and April 2022. Peripheral blood samples were collected at baseline, and clinical data were obtained from the electronic medical record system. Serum NRG1 concentrations were measured by enzyme-linked immunosorbent assay. Sanger sequencing was applied to detect the RNF213 p.R4810K mutation. ResultsThe serum NRG1 levels were significantly higher in MMD patients compared to controls (14.48 ± 10.81 vs.7.54 ± 6.35mmol/L, p < 0.001). No statistical difference in baseline clinical characteristics was found between both groups. Correlation analyses showed that NRG1 levels were positively associated with Suzuki staging (r = 0.4137, p = 0.023) while not related to other clinical features (reduced cerebral blood flow, posterior cerebral artery involvement, bilateral or unilateral steno-occlusive changes). Furthermore, subgroup analysis revealed that MMD patients with the RNF213 p.R4810K mutation presented with significantly higher NRG1 levels than those without the mutation (9.60 ± 0.929 vs. 25.89 ± 4.338 mmol/L, p = 0.001). ConclusionsOur study suggests that increased serum NRG1 levels may constitute a characteristic feature of MMD, indicating a potential positive correlation with disease progression and the presence of the RNF213 mutation. This positions NRG1 as a potentially crucial target for further studies aimed at comprehending the pathogenesis of MMD.

Metabolic profiling during COVID-19 infection in humans: Identification of potential biomarkers for occurrence, severity and outcomes using machine learning.

After its emergence in China, the coronavirus SARS-CoV-2 has swept the world, leading to global health crises with millions of deaths. COVID-19 clinical manifestations differ in severity, ranging from mild symptoms to severe disease. Although perturbation of metabolism has been reported as a part of the host response to COVID-19 infection, scarce data exist that describe stage-specific changes in host metabolites during the infection and how this could stratify patients based on severity. Given this knowledge gap, we performed targeted metabolomics profiling and then used machine learning models and biostatistics to characterize the alteration patterns of 50 metabolites and 17 blood parameters measured in a cohort of 295 human subjects. They were categorized into healthy controls, non-severe, severe and critical groups with their outcomes. Subject's demographic and clinical data were also used in the analyses to provide more robust predictive models. The non-severe and severe COVID-19 patients experienced the strongest changes in metabolite repertoire, whereas less intense changes occur during the critical phase. Panels of 15, 14, 2 and 2 key metabolites were identified as predictors for non-severe, severe, critical and dead patients, respectively. Specifically, arginine and malonyl methylmalonyl succinylcarnitine were significant biomarkers for the onset of COVID-19 infection and tauroursodeoxycholic acid were potential biomarkers for disease progression. Measuring blood parameters enhanced the predictive power of metabolic signatures during critical illness. Metabolomic signatures are distinctive for each stage of COVID-19 infection. This has great translation potential as it opens new therapeutic and diagnostic prospective based on key metabolites.

Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes.

Multiple system atrophy (MSA) is generally a sporadic neurodegenerative disease which ranks among atypical Parkinson's syndromes. The main clinical manifestation is a combination of autonomic dysfunction and parkinsonism and/or cerebellar disability. The disease may resemble other Parkinsonian syndromes, such as Parkinson's disease (PD) or progressive supranuclear palsy (PSP), from which MSA could be hardly distinguishable during the first years of progression. Due to the lack of a reliable and easily accessible biomarker, the diagnosis is still based primarily on the clinical picture. Recently, reduced levels of coenzyme Q10 (CoQ10) were described in MSA in various tissues, including the central nervous system. The aim of our study was to verify whether the level of CoQ10 in plasma and lymphocytes could serve as an easily available diagnostic biomarker of MSA. The study reported significantly lower levels of CoQ10 in the lymphocytes of patients with MSA compared to patients with PD and controls. The reduction in CoQ10 levels in lymphocytes correlated with the increasing degree of clinical involvement of patients with MSA. CoQ10 levels in lymphocytes seem to be a potential biomarker of disease progression.

Topological Network Analysis of Beta‐Amyloid and Tau in Alzheimer’s Disease Using PET Imaging Data

AbstractBackgroundAlzheimer’s disease (AD) is characterized by the presence of beta‐amyloid (Aβ) and tau in the brain. Understanding the interplay between these proteins and their spatial distribution may provide insights into disease progression. This study aims to investigate the topological features of Aβ and tau networks in AD, mild cognitive impairment (MCI), and normal cognition (NC) groups using PET images from the ADNI dataset.MethodPartial correlation matrices between the standardized uptake value ratio of 68 regions of interest (ROI’s) were used to generate networks for the AD, MCI, and NC groups, with nodes representing ROI’s and edges representing correlation coefficients. Topological features, including H0 features (connected components), H1 features (loops), and landscape functions of H1 features, were calculated for each sample’s persistent homology. For each group, 100 bootstrapping samples were used to generate the 95% confidence intervals for landscape functions. The connected components were further studied by representing the samples as hierarchical tree structures. In the tree space, the first few generated connections, representing the most consistent pairs of regions positive for Aβ and tau, were compared across groups. Clustering performances were compared using Wasserstein distance of H0 features, Wasserstein distance of H1 features, landscape function distance, and geodesic distance in tree space respectively.ResultThe geodesic distance in tree space showed the best clustering accuracy in both Aβ and tau analyses. Compared with Aβ, H1 features and the corresponding landscape functions performed better for tau. Unique connections in AD and MCI groups were identified, with AD showing more unique connections than MCI compared to NC samples. Dominant unique connections in the AD group included left‐right isthmus cingulate and left fusiform‐left inferior temporal for Aβ, and left‐right paracentral and left cuneus‐left pericalcarine for tau. These connections indicate region pairs with related concentrations of Aβ and tau in AD.ConclusionTopological network analysis can reveal complex underlying structures in PET images and identify consistent patterns in ROI’s associated with Aβ and tau localization. Tau aggregation exhibits more complex behavior than Aβ and is more strongly associated with AD. The identified unique connections in the AD group may serve as potential biomarkers for disease progression.

Plasma S-Evs Mirnas in Pediatric B Lineage Leukemia: Transforming Factors of Bone Marrow Niche

BACKGROUND Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and mature B-cell leukemia are characterized by dismal prognosis in case of relapse. Exosomes are crucial small extracellular vesicles (S-EVs) used by cells for intercellular communication, capable to modulate recipient cells through the release of small biological molecules (DNA, RNA, proteins). Tumor derived exosomes play an important role in leukemogenesis, disease progression, and organ invasion, due to their ability to induce molecular and functional changes within the bone marrow microenvironment (BME). Since little is known behind the mechanism used by leukemic cells to sustain tumor progression through exosomes release, this has become an exciting area to be investigated. OBJECTIVES This study aimed to provide novel insight about S-EVs-mediated small-RNA (sRNA) transfer within tumor niche and clarify how the crosstalk between tumor cells and cells from the microenvironment promote leukemia cells survival and progression. The characterization of leukemic S-EVs cargo led to the identification of new potential biomarkers of disease progression and treatments efficacy. DESIGN/METHODS RNA from plasma S-EVs samples of 17 mature B-cell leukemia, 16 BCP-ALL at diagnosis and 8 healthy donors (HD) were isolated and small-RNA sequencing on Illumina platform was performed; data were analyzed by miR&amp;moRe2 pipeline. MiRNAs levels were quantified by qRT-PCR in an extended cohort including HDs and patients both at diagnosis and during treatment. Mesenchymal stroma cells (MSCs) derived from healthy BM were co-cultured with tumor cell lines by using transwell. MSCs were also directly treated with S-EVs isolated from mature B-cell leukemia and BCP-ALL cell lines. S-EVs exchange was detected by confocal microscopy. Cell viability, migration and adipocyte differentiation assays were then assessed. Finally, pharmacological treatment of tumor cells co-cultured or not with adipocytes was administered. RESULTS Analysis of the profile of sRNAs contained in plasma exosomes according to sRNA-sequencing showed a peculiar miRNA cargo in both BCP-ALL and mature B cell leukemia groups compared to HD, and revealed 15 and 40 sRNAs significantly deregulated, respectively. We prioritized and validated the upregulation of 6 miRNAs (3 in BCP-ALL and 3 in mature B-cell leukemia) in an enlarged cohort patients' S-EVs obtained at diagnosis and in reference cell lines. Of note, the expression of these miRNAs during follow-up significantly decreases, suggesting their tumor origin and corroborating their usefulness as tumor biomarkers. To sustain this hypothesis sRNA-seq data were integrated with gene expression profiles obtained from leukemia blasts, underlining the tumor origin of these miRNAs. The prediction analysis of the miRNAs-target genes highlighted the alteration of specific networks related to cell survival, migration and cell differentiation. Furthermore, we demonstrated the communication via exosome release between leukemic cells and the surrounding cells and how S-EVs play a crucial role in the modulation of BME components. In particular, treatment with tumor derived S-EVs increases MSCs migration ability and prompts their adipogenic differentiation. These results were also confirmed by prioritized miRNAs transfection in MSCs. Co-culture of leukemic cells with adipocytes demonstrated their ability to protect BCP-ALL and mature B-cell leukemia cell lines from chemotherapy: leukemia cells showed a decrease in cell proliferation and a reduction of apoptosis. In line, poor responders BCP-ALL patients showed at diagnosis a positive enrichment in their transcriptome of mechanisms related to adipogenesis and lipids beta-oxidations. CONCLUSIONS Our data demonstrated that leukemic cells and BM niche cells efficiently communicate between each other through S-EVs release and uptake, inducing MSCs rewiring, with enhanced migratory and differentiative properties in vitro. We noted a strong enrichment of common pathways stroked by all the miRNA validated and related to lipid metabolism and sustenance of adipogenesis. Our study demonstrated that the bone marrow modulation is due to leukemic miRNAs shuttled by S-EVs in MSC cells and that the BME rewiring prompt leukemia chemoresistance.

Abstract PO-095: TGF-β carrying exosomes in plasma of HNSCC as potential biomarkers of disease progression in patients with HNSCC

Abstract Background: The contribution of TGFβ+ exosomes, now referred to as small extracellular vesicles (sEV), in plasma of cancer patients to disease progression has been unclear. Levels of TGFβ in plasma often do not correlate with clinicopathological data, and TGFβ can exert dual (yin-yang) effects as a tumor promoter and a tumor inhibitor. We evaluated the potential of tumor-derived sEV dubbed TEX to serve as liquid tumor biopsy in patients with HNSCC. Methods: Plasma was obtained from 3 different cohorts of patients with HNSCC (n=97) and HDs (n=22). Clinicopathology/demographic data were available for all patients. sEV were isolated by ultrafiltration/size exclusion chromatography (SEC) from plasma or cell supernatants. TGF-β levels in plasma were assessed by ELISA; TGF-β expression in tissues was studied by IHC and immunoblots; immunoblots, flow cytometry and LC-MS/MS were used to measure TGF-β in isolated sEV. TGFB1 gene expression was analyzed using the TCGA Head and Neck Cancer database (n=520 cases and 44 NC). TGF-β signaling and activity of EVs were quantified in the reporter cell (MFB-F11) proliferation assays. Changes of TGF-β expression levels in plasma, tissues and sEV during carcinogenesis were studied in an orthotopic 4NQO mouse model. Results: Using the TCGA we found high expression levels of the vesiculation genes regulating EV production/release and of the TGFB1 gene expression in HNSCC. In the 4NQO orthotopic model of OSCC, cancer progression correlated with TGF-β accumulations in tumor tissues and a significant increase in circulating TGF-β+ sEV. In HNSCC patients, TGF-β levels and activity in plasma and TGF-β expression levels in tumor tissues were significantly elevated relative to controls but did not correlate with clinicopathologic data, tumor burden or disease outcome. TEX produced by HNSCC cell lines carried TGF-β and initiated Smad3 signaling in reporter cells. TGF-β inhibitors blocked this signaling. High TGFβ abundance in sEV was confirmed by proteomics and by RNAseq using the TCGA data base. Levels of TGF-β expression in sEV, sEV numbers and TGF-β activity of sEV were significantly elevated in HNSCC patients vs HDs’ sEV and correlated with tumor stage and LN involvement. Conclusions: TEX and sEV from HNSCC patients’ plasma carry TGF-β which reflects disease progression in HNSCC patients and in a mouse model of oral carcinogenesis. Neither plasma levels of TGF-β (ELISA) nor levels of TGF-β expression in the tumor (IHC) correlated with disease progression. Only sEV-associated TGF-β correlates with tumor burden and shows promise as a non-invasive biomarker of HNSCC progression and response to therapy. Citation Format: Nils Ludwig, Saigopalakrishna S. Yerneni, Theresa L. Whiteside. TGF-β carrying exosomes in plasma of HNSCC as potential biomarkers of disease progression in patients with HNSCC [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-095.

Role of viral load and host cytokines in determining the disease severity of Respiratory Syncytial Virus associated acute lower respiratory tract infections in children.

Respiratory syncytial virus disease (RSV) is an important cause of acute lower respiratory tract infection. This study aimed to evaluate the role of viral load and cytokines, including MMP-9 and TIMP-1, in determining the severity of RSV disease and to identify potential biomarkers of disease severity. 142 patients of RSV (>2 months to <5 years of age) presenting with acute lower respiratory tract infection (ALRTI) between December 2013 to March 2016 were enrolled. Their nasopharyngeal aspirate was subjected to RSV viral load quantification and local cytokine levels of IL-6, TNF, IL-17A, IFN-Ƴ and IL-10 as determined using cytokine bead array. Levels of MMP-9 and TIMP-1 were calculated using Quantikine ELISA on 109 aspirates. These parameters were compared against different categories of disease severity. A higher viral load and increased levels of TNFα, MMP-9 and MMP-9:TIMP-1 were associated with greater severity of disease; while levels of IL-17a, IFN-Ƴ, and IFN-Ƴ:IL-10 were associated with disease resolution. In defining transition from non-severe to severe disease, MMP-9 had a sensitivity and specificity of 89.7% and 85.4%, respectively and MMP-9:TIMP-1 had a sensitivity and specificity of 87.2% and 76.8% respectively. Hence, MMP-9, MMP-9:TIMP-1, TNFα and IL-10 could serve as potential biomarkers for disease progression in RSV-infected children.

Multimodal MRI improves diagnostic accuracy and sensitivity to longitudinal change in amyotrophic lateral sclerosis

BackgroundRecent advances in MRI acquisitions and image analysis have increased the utility of neuroimaging in understanding disease-related changes. In this work, we aim to demonstrate increased sensitivity to disease progression as well as improved diagnostic accuracy in Amyotrophic lateral sclerosis (ALS) with multimodal MRI of the brain and cervical spinal cord.MethodsWe acquired diffusion MRI data from the brain and cervical cord, and T1 data from the brain, of 20 participants with ALS and 20 healthy control participants. Ten ALS and 14 control participants, and 11 ALS and 13 control participants were re-scanned at 6-month and 12-month follow-ups respectively. We estimated cross-sectional differences and longitudinal changes in diffusion metrics, cortical thickness, and fixel-based microstructure measures, i.e. fiber density and fiber cross-section.ResultsWe demonstrate improved disease diagnostic accuracy and sensitivity through multimodal analysis of brain and spinal cord metrics. The brain metrics also distinguished lower motor neuron-predominant ALS participants from control participants. Fiber density and cross-section provided the greatest sensitivity to longitudinal change. We demonstrate evidence of progression in a cohort of 11 participants with slowly progressive ALS, including in participants with very slow change in ALSFRS-R. More importantly, we demonstrate that longitudinal change is detectable at a six-month follow-up visit. We also report correlations between ALSFRS-R and the fiber density and cross-section metrics.ConclusionsOur findings suggest that multimodal MRI is useful in improving disease diagnosis, and fixel-based measures may serve as potential biomarkers of disease progression in ALS clinical trials.

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy (S14.001)

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy (S14.001)

Protein Profiling in Human Papillomavirus-Associated Cervical Carcinogenesis: Cornulin as a Biomarker for Disease Progression

Nearly 90% of cervical cancers are linked to human papillomavirus (HPV). Uncovering the protein signatures in each histological phase of cervical oncogenesis provides a path to biomarker discovery. The proteomes extracted from formalin-fixed paraffin-embedded tissues of the normal cervix, HPV16/18-associated squamous intraepithelial lesion (SIL), and squamous cell carcinoma (SCC) were compared using liquid chromatography-mass spectrometry (LC-MS). A total of 3597 proteins were identified, with 589, 550, and 1570 proteins unique to the normal cervix, SIL, and SCC groups, respectively, while 332 proteins overlapped between the three groups. In the transition from normal cervix to SIL, all 39 differentially expressed proteins were downregulated, while all 51 proteins discovered were upregulated in SIL to SCC. The binding process was the top molecular function, while chromatin silencing in the SIL vs. normal group, and nucleosome assembly in SCC vs. SIL groups was the top biological process. The PI3 kinase pathway appears crucial in initiating neoplastic transformation, while viral carcinogenesis and necroptosis are important for cell proliferation, migration, and metastasis in cervical cancer development. Annexin A2 and cornulin were selected for validation based on LC-MS results. The former was downregulated in the SIL vs. normal cervix and upregulated in the progression from SIL to SCC. In contrast, cornulin exhibited the highest expression in the normal cervix and lowest in SCC. Although other proteins, such as histones, collagen, and vimentin, were differentially expressed, their ubiquitous expression in most cells precluded further analysis. Immunohistochemical analysis of tissue microarrays found no significant difference in Annexin A2 expression between the groups. Conversely, cornulin exhibited the strongest expression in the normal cervix and lowest in SCC, supporting its role as a tumor suppressor and potential biomarker for disease progression.

"Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions.

The superfamily of serine protease inhibitors (SERPINs) are a class of inhibitors that utilise a dynamic conformational change to trap and inhibit their target enzymes. Their powerful nature lends itself well to regulation of complex physiological enzymatic cascades, such as the haemostatic, inflammatory and complement pathways. The SERPINs α2-antiplasmin, plasminogen-activator inhibitor-1, plasminogen-activator inhibitor-2, protease nexin-1, and C1-inhibitor play crucial inhibitory roles in regulation of the fibrinolytic system and inflammation. Elevated levels of these SERPINs are associated with increased risk of thrombotic complications, obesity, type 2 diabetes, and hypertension. Conversely, deficiencies of these SERPINs have been linked to hyperfibrinolysis with bleeding and angioedema. In recent years SERPINs have been implicated in the modulation of the immune response and various thromboinflammatory conditions, such as sepsis and COVID-19. Here, we highlight the current understanding of the physiological role of SERPINs in haemostasis and inflammatory disease progression, with emphasis on the fibrinolytic pathway, and how this becomes dysregulated during disease. Finally, we consider the role of these SERPINs as potential biomarkers of disease progression and therapeutic targets for thromboinflammatory diseases.

Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes.

A number of studies have demonstrated a key role of miRNA isolated from cells, tissue or body fluids as disease-specific biomarkers of autoimmune rheumatic diseases including rheumatoid arthritis (RA) and systemic sclerosis (SSc). Also, the expression level of miRNA is changing during disease development, therefore miRNA can be used as biomarkers monitoring RA progression and treatment response. In this study we have investigated the monocytes-specific miRNA that could serve as potential biomarkers of disease progression observed in sera and synovial fluids (SF) in early (eRA) and advanced (aRA) RA and in RA patients before and 3 months after selective JAK inhibitor (JAKi) -baricitinib treatment. Samples from healthy control (HC) (n=37), RA (n=44) and SSc (n=10) patients were used. MiRNA-seq of HC, RA, and SSc monocytes was performed to find versatile miRNA present in different rheumatic diseases. Selected miRNAs were validated in body fluids in eRA (<2 years disease onset) and aRA (>2 years disease onset) and RA patients receiving baricitinib. Using miRNA-seq, we selected top 6 miRNA out of 95 that were significantly changed in both RA and SSc monocytes compared to HC. To identify circulating miRNA predicting RA progression, these 6 miRNA were measured in eRA and aRA sera and SF. Interestingly, miRNA (-19b-3p, -374a-5p, -3614-5p) were significantly increased in eRA sera vs HC and even further upregulated in SF vs aRA sera. In contrast, miRNA-29c-5p was significantly reduced in eRA sera vs HC and even further decreased in SF vs aRA sera. Kegg pathway analysis predicted that miRNA were involved in inflammatory-mediated pathways. ROC analysis demonstrated that miRNA-19b-3p (AUC=0.85, p=0.04) can be used as biomarker predicting JAKi response. In conclusion, we identified and validated miRNA candidates which were present simultaneously in monocytes, sera, SF and that can be used as biomarkers predicting joint inflammation and monitoring therapy response to JAKi in RA patients.

Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution.

In this study, we conducted a quantitative serum analysis of 7 immunoglobulins in CLL and monoclonal B-cell lymphocytosis (MBL) patients (bead-suspension protein arrays) and a serological profile (IgG and IgM) study of autoantibodies and antimicrobial antigens (protein microarrays). Significant differences in the IgA levels were observed according to disease progression and evolution as well as significant alterations in IgG1 according to IGHV mutational status. More representative IgG autoantibodies in the cohort were against nonmutagenic proteins and IgM autoantibodies were against vesicle proteins. Antimicrobial IgG and IgM were detected against microbes associated with respiratory tract infections. Quantitative differences in immunoglobulin serum levels could be potential biomarkers for disease progression. In the top 5 tumoral antigens, we detected autoantibodies (IgM and IgG) against proteins related to cell homeostasis and metabolism in the studied cohort. The top 5 microbial antigens were associated with respiratory and gastrointestinal infections; moreover, the subsets with better prognostics were characterized by a reactivation of Cytomegalovirus. The viral humoral response could be a potential prognosis biomarker for disease progression.

Neurofilament light as a marker of neuro‐axonal injury and potential biomarker of disease progression in normal pressure hydrocephalus

AbstractBackgroundThe etiology of normal pressure hydrocephalus (NPH) is unknown. Patients worsen but the cause of the progression is unclear. A prognostic biomarker in NPH is required for selecting the best candidates for shunt surgery. Neurofilament‐light chain (NfL) is a marker of neuro‐axonal injury and is elevated in neurodegenerative disease, traumatic brain injury, stroke and encephalitis. The aim of this study was: (1) To compare cerebrospinal fluid (CSF) NfL of NPH patients with healthy controls (HC), and other neurodegenerative diseases: Alzheimer’s disease (AD), and Frontotemporal lobar degeneration (FTLD); and (2) To evaluate CSF NfL levels as a potential biomarker of disease progression in NPH.Method108 patients with CSF analysis: (a) NPH group (39 patients): ventriculomegaly on MRI or CT, negative AD biomarkers, clinical symptoms of NPH, improvement in gait after removal of a large amount of CSF. 14 patients of the unshunted NPH group had a 1‐year follow‐up scan. EVANS index was calculated for these participants; (b) FTLD group (45 patients): 5 behavioural‐variant frontotemporal‐dementia, 19 corticobasal syndrome, 3 frontotemporal dementia with motor neuron disease, 13 progressive supranuclear palsy, 3 semantic‐variant primary progressive aphasia (PPA), and 2 non‐fluent PPA; (c) AD group (19 patients): CSF biomarkers and cognitive symptoms consistent with AD; and (d) HC group (5 participants): cognitively and functionally normal. Levels of NfL in CSF were measured using single molecule array (Simoa) technology. All statistical analyses were corrected for multiple comparisons and age.ResultNfL levels in patients with NPH were significantly higher than HC (1504.7±520 vs 702.5±170pg/ml, p &lt; 0.001), and lower than FTLD group (1504.7±520 vs 3071.7±2830pg/ml, p=0.005). There was a trend for lower NfL in NPH compared to AD, (1504.7±520 vs 2305.4±1179.7pg/ml, p=0.056). There was a significant correlation between baseline NfL levels and increase in EVANS index (r=0.784, p=0.002) in the 14 NPH patients with longitudinal brain imaging.ConclusionCSF NfL levels in NPH patients suggests there is neuro‐axonal injury but is lower than some other neurodegenerative diseases (i.e., FTLD and AD). NfL may be a biomarker for neuro‐axonal injury and disease progression in NPH.

Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease.

Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years. Observational data in this cohort is lacking. Quantify measures of disease progression for use in clinical trials of patients with JOHD. Participants who received a motor diagnosis of HD before the age of 21 were included in the Kids-JOHD study. The comparator group consisted of children and young adults who were at-risk for inheriting the genetic mutation that causes HD, but who were found to have a CAG repeat in the non-expanded range (gene non-expanded [GNE]). Data were obtained between March 17, 2006, and February 13, 2020. There were 26 JOHD participants and 78 GNE participants who were comparable on age (16.03 vs. 14.43, respectively) and sex (53.8% female vs. 57.7% female, respectively). The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE (mean difference [MD], -3.93%; 95% confidence intervals [CI], [-4.98 to -2.80], FDR < 0.0001). The mean increase in the Unified Huntington's Disease Rating Scale Total Motor Score per year in the JOHD group was 7.29 points compared to a mean decrease of -0.21 point in the GNE (MD,7.5; 95% CI, [5.71-9.28], FDR < 0·0001). These findings demonstrate that structural brain imaging and clinical measures in JOHD may be potential biomarkers of disease progression for use in clinical trials. Collaborative efforts are required to validate these results in a larger cohort of patients with JOHD. © 2022 International Parkinson and Movement Disorder Society.

Progressive Spinal Cord Degeneration in Friedreich's Ataxia: Results from ENIGMA-Ataxia.

Spinal cord damage is a hallmark of Friedreich's ataxia (FRDA), but its progression and clinical correlates remain unclear. The objective of this study was to perform a characterization of cervical spinal cord structural damage in a large multisite FRDA cohort. We performed a cross-sectional analysis of cervical spinal cord (C1-C4) cross-sectional area (CSA) and eccentricity using magnetic resonance imaging data from eight sites within the ENIGMA-Ataxia initiative, including 256 individuals with FRDA and 223 age- and sex-matched control subjects. Correlations and subgroup analyses within the FRDA cohort were undertaken based on disease duration, ataxia severity, and onset age. Individuals with FRDA, relative to control subjects, had significantly reduced CSA at all examined levels, with large effect sizes (d> 2.1) and significant correlations with disease severity (r< -0.4). Similarly, we found significantly increased eccentricity (d> 1.2), but without significant clinical correlations. Subgroup analyses showed that CSA and eccentricity are abnormal at all disease stages. However, although CSA appears to decrease progressively, eccentricity remains stable over time. Previous research has shown that increased eccentricity reflects dorsal column (DC) damage, while decreased CSA reflects either DC or corticospinal tract (CST) damage, or both. Hence our data support the hypothesis that damage to the DC and damage to CST follow distinct courses in FRDA: developmental abnormalities likely define the DC, while CST alterations may be both developmental and degenerative. These results provide new insights about FRDA pathogenesis and indicate that CSA of the cervical spinal cord should be investigated further as a potential biomarker of disease progression. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

MicroRNA-204/CREB5 axis regulates vasculogenic mimicry in breast cancer cells.

Vasculogenic mimicry (VM) is characterized by formation of three-dimensional (3D) channels-like structures by tumor cells, supplying the nutrients needed for tumor growth. VM is stimulated by hypoxic tumor microenvironment, and it has been associated with increased metastasis and clinical poor outcome in cancer patients. cAMP responsive element (CRE)-binding protein 5 (CREB5) is a hypoxia-activated transcription factor involved in tumorigenesis. However, CREB5 functions in VM and if its regulated by microRNAs remains unknown in breast cancer. We aim to study the functional relationships between VM, CREB5 and microRNA-204-5p (miR-204) in breast cancer cells. CREB5 expression was evaluated by mining the public databases, and using RT-qPCR and Western blot assays. CREB5 expression was silenced using short-hairpin RNAs in MDA-MB-231 and MCF-7 breast cancer cells. VM formation was analyzed using matrigel-based cultures in hypoxic conditions. MiR-204 expression was restored in cancer cells by transfection of RNA mimics. Luciferase reporter assays were performed to evaluate the binding of miR-204 to 3'UTR of CREB5. Our data showed that CREB5 mRNA expression was upregulated in a set of breast cancer cell lines and clinical tumors, and it was positively associated with poor prognosis in lymph nodes positive and grade 3 basal breast cancer patients. Silencing of CREB5 impaired the hypoxia-induced formation of 3D channels-like structures representative of the early stages of VM in MDA-MB-231 cells. In contrast, VM formation was not observed in MCF-7 cells. Interestingly, we found that CREB5 expression was negatively regulated by miR-204 mimics in breast cancer cells. Functional analysis confirmed that miR-204 binds to CREB5 3'-UTR indicating that it's an ulterior effector. Our findings suggested that CREB5 could be a potential biomarker of disease progression in basal subtype of breast cancer, and that perturbations of the miR-204/CREB5 axis plays an important role in VM development in breast cancer cells.

Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models

Increased protein citrullination (PC) and dysregulated protein arginine deiminase (PAD) activity have been observed in several neurodegenerative diseases. PC is a posttranslational modification catalyzed by the PADs. PC converts peptidyl-arginine to peptidyl-citrulline, thereby reducing the positive charges and altering structure and function of proteins. Of the five PADs, PAD2 is the dominant isoform in the central nervous system (CNS). Abnormal PC and PAD dysregulation are associated with numerous pathological conditions, including inflammatory diseases and neurodegeneration. Animal model studies have shown therapeutic efficacy from inhibition of PADs, thus suggesting a role of PC in pathogenesis. To determine whether PC contribute to amyotrophic lateral sclerosis (ALS), a deadly neurodegenerative disease characterized by loss of motor neurons, paralysis, and eventual death, we investigated alterations of PC and PAD2 in two different transgenic mouse models of ALS expressing human mutant SOD1G93A and PFN1C71G, respectively. PC and PAD2 expression are altered dynamically in the spinal cord during disease progression in both models. PC and PAD2 increase progressively in astrocytes with the development of reactive astrogliosis, while decreasing in neurons. Importantly, in the spinal cord white matter, PC accumulates in protein aggregates that contain the myelin proteins PLP and MBP. PC also accumulates progressively in insoluble protein fractions during disease progression. Finally, increased PC and PAD2 expression spatially correlate with areas of the CNS with the most severe motor neuron degeneration. These results suggest that altered PC is an integral part of the neurodegenerative process and potential biomarkers for disease progression in ALS. Moreover, increased PC may contribute to disease-associated processes such as myelin protein aggregation, myelin degeneration, and astrogliosis.